XPH: TAEST1901 injection has received approval for clinical trials
I'm PortAI, I can summarize articles.
The subsidiary of XPH, Xiangxue Life Sciences, has received approval from the National Medical Products Administration for the clinical trial application of the new drug TAEST1901 injection. This drug is suitable for the treatment of advanced gastric cancer with the genotype HLA-A*02:01 and positive expression of the tumor antigen AFP
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments